Meet Resonant Labs: The Geelong Deep-Tech Startup You Need to Know About This Month

Resonant Labs, a three-year-old deep-tech startup based on Gheringhap Street in central Geelong, has just secured $2.8 million in Series A funding—a significant milestone that positions the company as one of the region's most promising ventures in the neurotechnology space.

The company's core innovation centres on signal-processing algorithms that decode neural activity with unprecedented precision, enabling faster and more reliable communication between the human brain and external devices. Unlike consumer-facing brain-tech ventures capturing headlines elsewhere, Resonant Labs is focused squarely on medical applications: helping stroke survivors regain motor control and assisting paralysed patients with prosthetic limbs.

"What's remarkable about Resonant Labs is they're solving a genuinely hard problem," says Dr. Christine Wade, director of the Geelong Innovation Precinct, which occupies heritage buildings near Johnstone Park. "Neural signal noise has been a constraint for decades. Their approach to filtering and pattern recognition is novel, and it's attracting interest from research hospitals across Australia and beyond."

Founded by neuroscientist Dr. Sanjay Patel and software engineer Marcus Chen, Resonant Labs employs 24 people—roughly half drawn from Deakin University's engineering and health sciences faculties. The startup occupies a 1,200-square-metre workspace in the Precinct, where they operate testing facilities and collaborate closely with clinical partners at Barwon Health.

The funding announcement, confirmed late last month, came from a mix of Australian venture capital firms and international deep-tech investors. It caps an 18-month period during which Resonant Labs published three peer-reviewed papers on neural decoding and completed successful trials with seven human participants recovering from stroke.

What sets them apart in Geelong's growing tech ecosystem—which includes software firms, manufacturing tech companies, and digital agencies—is their willingness to invest in multi-year research cycles before revenue becomes viable. Most startup founders in the region focus on faster-to-market solutions. Resonant Labs is betting that patience, rigour, and specialisation will pay off in an expanding medical-device sector worth an estimated $180 billion globally.

Their next milestone: FDA pre-submission meetings scheduled for September, a crucial step toward commercialising their first clinical device in North America by 2027. For Geelong, it's a reminder that the city's tech narrative extends well beyond software. Deep science, combined with local talent and institutional support, is quietly building something substantial here.

This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.